Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial - PubMed

ClinicalTrials.gov Identifier: NCT04397770.
pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov